Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Jane Wright-Mitchell net worth and biography

Jane Wright-Mitchell Biography and Net Worth

General Counsel of Vaxcyte

Jane Wright-Mitchell occupies the position of Secretary & Chief Compliance Officer for Vaxcyte, Inc.

In the past she was Assistant General Counsel at Purdue Pharma LP, Associate of Michael Best & Friedrich LLP, Assistant General Counsel at NeurogesX, Inc., Secretary, Chief Legal & Compliance Officer at AcelRx Pharmaceuticals, Inc., Senior Manager-Regulatory Affairs at Abbott Laboratories, Chief Legal Officer at Steep Hill, Inc., Associate General Counsel at Mesoblast, Inc. and Director-Legal Affairs at Actelion Pharmaceuticals US, Inc.

Ms. Wright-Mitchell received a graduate degree from Chicago-Kent College of Law, an undergraduate degree from the University of Illinois and an undergraduate degree from Clemson University.

How do I contact Jane Wright-Mitchell?: The corporate mailing address for Ms. Wright-Mitchell and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Jane Wright-Mitchell's contact information.
Has Jane Wright-Mitchell been buying or selling shares of Vaxcyte?: Jane Wright-Mitchell has not been actively trading shares of Vaxcyte over the course of the past ninety days. Most recently, Jane Wright-Mitchell sold 2,500 shares of the business's stock in a transaction on Monday, August 16th. The shares were sold at an average price of $26.00, for a transaction totalling $65,000.00. Learn More on Jane Wright-Mitchell's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 49 times. They sold a total of 427,456 shares worth more than $35,141,433.71. The most recent insider tranaction occured on December, 18th when CFO Andrew Guggenhime sold 8,000 shares worth more than $710,240.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 12/18/2024.

Jane Wright-Mitchell Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/16/2021	Sell	2,500	$26.00	$65,000.00
8/12/2021	Sell	10,000	$26.00	$260,000.00
1/15/2021	Sell	2,500	$26.00	$65,000.00

Jane Wright-Mitchell Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $86.53

$86.25

$88.90

50 Day Range

MA: $98.70

$85.75

$117.93

2 Week Range

Now: $86.53

$53.83

$121.06

Volume

3,859,357 shs

Average Volume

922,601 shs

Market Capitalization

$10.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

First JFK… next Elon?

From Porter & Company | Ad